Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

Treatment of osteoporosis is aimed to prevent fragility fractures and to stabilize or increase bone mineral density. Several drugs with different efficacy and safety profiles are available. The long-term therapeutic strategy should be planned, and the initial treatment should be selected according to the individual site-specific fracture risk and the need to give the maximal protection when the fracture risk is highest (i.e. in the late life). The present consensus focused on the strategies for the treatment of postmenopausal osteoporosis taking into consideration all the drugs available for this purpose. A short revision of the literature about treatment of secondary osteoporosis due both to androgen deprivation therapy for prostate cancer and to aromatase inhibitors for breast cancer was also performed. Also premenopausal females and males with osteoporosis are frequently seen in endocrine settings. Finally particular attention was paid to the tailoring of treatment as well as to its duration.Electronic supplementary materialThe online version of this article (doi:10.1007/s40618-016-0434-8) contains supplementary material, which is available to authorized users.

show abstract

“…Oral risedronate significantly recovered BMD for up to 24 months compared with the control group after starting ADT [ 186 ].…”

Section: Other Forms Of Osteoporosismentioning

confidence: 99%

Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis

Vescini

Attanasio

Antonio

et al. 2016

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

Osteoporose beim Mann mit hormonablativer Therapie bei nicht-metastasiertem Prostatakarzinom

Kudlacek

Puntus

2012

Wien Med Wochenschr

View full text Add to dashboard Cite

Osteoporosis is defined as a continuous loss of bone mineral density accompanied by an increased fracture risk in females and males. A fall of estrogen concentrations at the menopause and the consecutive rapid bone loss are an established pathogenic mechanism in female osteoporosis. Males do not have a menopause equivalent during which significant amounts of bone are lost. Several diseases, therapeutic strategies and nutritional deficiencies may also result in bone loss and reduced bone mineral density. Prostate cancer is the most common visceral malignancy in men. Suppression of endogenous androgen production as a therapeutic tool is commonly used in patients with non-metastatic prostate cancer and is associated with significant bone loss and an increased fracture risk. Androgen deprivation therapy is prescribed both for men with locally advanced or high-risk non-metastatic prostate cancer. Osteoclast inhibition with any of several bisphosphonates improves bone mineral density and reduces fracture risk. Denosumab (a monoclonal antibody against RANK ligand) and toremifene (a selective estrogen receptor modulator) recently have been shown to be effective to reduce vertebral fractures in patients with non-metastatic prostate cancer receiving androgen-deprivation therapy. This overview focuses on cancer-treatment-induced bone loss in patients with non-metastatic prostate cancer.

show abstract

Muscle and bone effects of androgen deprivation therapy: current and emerging therapies

Cheung¹,

Zajac²,

Grossmann³

2014

Endocrine Related Cancer

View full text Add to dashboard Cite

Prostate cancer and treatment with androgen deprivation therapy (ADT) affect significant numbers of the male population. Endocrine effects of ADT are a critical consideration in balancing the benefits and risks of treatment on long-term survival and quality of life. This review highlights the latest advances in androgen manipulation in prostate cancer with an emphasis on the effects of ADT on muscle and bone, which universally affects the health and well-being of men undergoing ADT for prostate cancer. Muscle mass declines with ADT; however, the evidence that this correlates with a decrease in muscle strength or a decrease in physical performance is discordant. Cortical bone decay also occurs in association with an increase in fracture risk, hence optimization of musculoskeletal health in men undergoing ADT is crucial. The role of exercise, and current and emerging anabolic therapies for muscle as well as various new strategies to prevent loss of bone mass in men undergoing ADT are discussed. Future well-designed, prospective, controlled studies are required to elucidate the effects of ADT on physical performance, which are currently lacking, and larger randomized controlled trials are required to test the efficacy of medical therapies and exercise interventions to target proven deficits and to ensure safety in men with prostate cancer.

show abstract

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

Cited by 5 publications

References 30 publications

Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis

Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis

Osteoporose beim Mann mit hormonablativer Therapie bei nicht-metastasiertem Prostatakarzinom

Muscle and bone effects of androgen deprivation therapy: current and emerging therapies

Contact Info

Product

Resources

About